1. Home
  2. CMND vs VRAX Comparison

CMND vs VRAX Comparison

Compare CMND & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMND
  • VRAX
  • Stock Information
  • Founded
  • CMND 2017
  • VRAX 2013
  • Country
  • CMND Canada
  • VRAX United Kingdom
  • Employees
  • CMND N/A
  • VRAX N/A
  • Industry
  • CMND Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CMND Health Care
  • VRAX Health Care
  • Exchange
  • CMND Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • CMND 6.0M
  • VRAX 7.3M
  • IPO Year
  • CMND N/A
  • VRAX 2022
  • Fundamental
  • Price
  • CMND $1.13
  • VRAX $1.29
  • Analyst Decision
  • CMND
  • VRAX
  • Analyst Count
  • CMND 0
  • VRAX 0
  • Target Price
  • CMND N/A
  • VRAX N/A
  • AVG Volume (30 Days)
  • CMND 56.1K
  • VRAX 194.7K
  • Earning Date
  • CMND 04-15-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • CMND N/A
  • VRAX N/A
  • EPS Growth
  • CMND N/A
  • VRAX N/A
  • EPS
  • CMND N/A
  • VRAX N/A
  • Revenue
  • CMND N/A
  • VRAX $84,872.00
  • Revenue This Year
  • CMND N/A
  • VRAX $5,169.18
  • Revenue Next Year
  • CMND N/A
  • VRAX $66.97
  • P/E Ratio
  • CMND N/A
  • VRAX N/A
  • Revenue Growth
  • CMND N/A
  • VRAX 7.03
  • 52 Week Low
  • CMND $0.95
  • VRAX $0.60
  • 52 Week High
  • CMND $2.30
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • CMND 39.96
  • VRAX 33.99
  • Support Level
  • CMND $1.05
  • VRAX $1.22
  • Resistance Level
  • CMND $1.16
  • VRAX $1.84
  • Average True Range (ATR)
  • CMND 0.06
  • VRAX 0.18
  • MACD
  • CMND -0.00
  • VRAX -0.02
  • Stochastic Oscillator
  • CMND 27.30
  • VRAX 9.59

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: